Attovia Therapeutics, Inc. (ATTO) Stock Score, Valuation & Financial Research

Attovia Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ATTO

Attovia Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 17.14. These figures are a research snapshot, not a buy or sell recommendation.

What Attovia Therapeutics, Inc. does

A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Attovia Therapeutics is a clinical-stage biopharmaceutical company that generates no commercial revenue. Its business model relies on raising capital through equity offerings and potential future licensing or collaboration agreements to fund the research and development of its proprietary ATTOBODY biologics platform for immune-mediated diseases.

Products and services

  • The company is developing a pipeline of biotherapeutics including ATTO-1310 (anti-IL-31 for chronic pruritic diseases), ATTO-2306 (bispecific targeting IL-31 and IL-13), and ATTO-1091 (trispecific targeting TL1A, IL-23p19, and integrin a4b7).

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company utilizes third-party contract manufacturing organizations for the production of its clinical-stage product candidates. Source

Business strengths to evaluate

  • Proprietary ATTOBODY biologics platform Source

Business risks and research considerations

  • Clinical development and regulatory approval risks Source
  • Dependence on additional capital to fund operations Source

Sources: Company research source · Proprietary ATTOBODY biologics platform

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ATTO financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 17.14
Market capitalization:
737.53M (currency not supplied)
Revenue:
USD 1.35M
Net income:
USD -60.63M
Free cash flow:
USD -61.51M
Cash:
USD 32.83M
Total debt:
USD 4.33M
EPS:
USD -1.42

What stands out

  • Free cash flow is USD -61.51M, negative for the stored period.
  • The balance sheet shows USD 32.83M of cash versus USD 4.33M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -4556.4% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -4490.9% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 28.5M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ATTO

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ATTO fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ATTO likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ATTO to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of ATTO's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research ATTO

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.